volume 28, issue 2, P136-144 2007
DOI: 10.2500/aap.2007.28.2980
View full text
|
Sign up to set email alerts
|
Share

Abstract: The Food and Drug Administration approved new safety labeling on March 2, 2006 for medication containing salmeterol, a long-acting beta-agonist (LABA), because of data suggesting an increased risk of fatal or potentially fatal asthma episodes. The "black box" warning, public health advisory, and label change for salmeterol, salmeterol-fluticasone combination, and formoterol has heightened public and physician concern over the risk-to-benefit ratio and the medicolegal implications of prescribing these agents fo…

Expand abstract